CombiMatrix Corporation (NASDAQ:CBMX) & Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Slipping Lower

Fernando Stephens
June 20, 2017

Adamis Pharmaceuticals Corporation (ADMP) closed its previous trading session at $5.1 with the loss of -1.92%. Sterling Global Strategies LLC now owns 42,600 shares of the specialty pharmaceutical company's stock worth $181,000 after buying an additional 2,600 shares in the last quarter. Wall Street analysts covering the stock are projecting that the stock will reach $10 within the next 52-weeks. A beta of less than 1 means that the security will be less volatile than the market.

Analysts on average have given a price target of $10 to Adamis Pharmaceuticals Corporation (ADMP) stock.

Currently, EPS of Adamis Pharmaceuticals Corporation (ADMP) is -0.26 while the analysts predicted the EPS of the stock to be -0.2 suggesting the company fell short of the analysts' expectations.

Adamis Pharmaceuticals Corporation (ADMP) has a market capitalization of 143.33 Million which suggests the company is a huge company further suggesting that the shares of Adamis Pharmaceuticals Corporation (ADMP) are stable and safe compared to the lower market capitalization companies.

Muslim girl killed in Virginia; police blame "road rage"
Hassanen's mother, Sawsan Gazzar, reportedly told the Washington Post that Nabra was beaten with a metal bat. At around 3pm, the remains of a female believed to be the teen victim were found in a pond, said the police.

ATR value of company was 0.53. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report 0.36 earnings per share. The company has its outstanding shares of 303.50 million.

Adamis Pharmaceuticals Corporation (ADMP) will report its next earnings on May 19. The company posted an earnings surprise of -30%. Alpha One also gave press coverage about the specialty pharmaceutical company an impact score of 48 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. The Lower end of the earnings estimate is $-0.13, while the higher end of the earnings estimate is $-0.13.

Adamis Pharmaceuticals Corporation's 20-Day Simple Moving Average is 15.76%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 5.48%. Important factors to focus when evaluating a stock's present and future value are the 52 week price high and low levels. Similarly, the company's last 5 years high P/E ratio is 0 and low P/E is 0, whereas, the industry's and sector's high P/E for the past year is 40 and 45.45 respectively and low P/E ratio for the last 5 years is 22.67 for the industry and 23.78 for the Sector. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 52.09% since June 20, 2016 and is downtrending. Its book value per share for the most recent quarter is $0.94 while its price to book ratio for the same period is 5.53, as for as the company's cash per share for the most recent quarter is $0.01, however its price to cash per share ratio for the same period is 396.24.

Other reports by BadHub

Discuss This Article